Anti-B16F10 antibodies secreted by tumor-infiltrating B cells are expected to enhance the effects of CD8+ and NK cell infiltration through the mechanisms of antibody-dependent cellular cytotoxicity and by activating the complement system [36,37]. The gene discussed is CD8A; the disease is neoplasm.